leadf
logo-loader
ASX:PAR

Paradigm Biopharmaceuticals Ltd

Receive alerts
Market:
ASX
Market Cap:
$482.8 m
Price
2.10 AUD
Change
2.44%
52 weeks high
3.19
52 weeks low
1.76

In brief

Paradigm Biopharmaceuticals Ltd (ASX:PAR) is a drug repurposing company driven by core competencies and experience at board and executive level in clinical and commercial pharmaceutical development.

The company’s approach is to take an existing approved drug, which has demonstrated safety in its approved indications, and repurposing the drug in a new patented therapeutic application.

Paradigm’s pipeline indications cover the use of pharmaceutical compound Pentosan Polysulfate Sodium (PPS), supported by full patent and IP protection and its immediate commercial focus is the repurposing of PPS for the treatment of Osteoarthritis (OA).

Snapshot

  • Paradigm Biopharmaceuticals granted Australian ethics approval for pivotal Phase 3 clinical trial in participants with knee OA
  • Paradigm Biopharmaceuticals in new collaboration with bene pharmaChem to co-fund new projects to unlock potential of injectable PPS
  • Paradigm Biopharmaceuticals secures first revenues for Zilosul

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Paradigm Biopharmaceuticals in new collaboration with bene pharmaChem to co-fund new projects to unlock potential of injectable PPS

Under the new agreement, both parties have agreed to jointly fund the R&D and work collaboratively on new Intellectual Property creation, which Paradigm will commercialise. 

on 31/3/21